Several studies have reported that SIX1 overexpression is frequently associated with poor patient prognosis in various malignancies, as colorectal cancer (Kahlert et al., 2015) and glioma (Zhang and Xu, 2017), however not in melanoma. Here, SIX1 is linked to central nervous system cancer.